Edgar Filing: Capponi Vincent - Form 4

Capponi Vii Form 4	ncent									
June 18, 201	18									
FORM	14 UNITED	STATES S	ECUR	ITIES A	ND EX(THAT	NGE CO	OMMISSION		PROVAL
	UNITED	STATES							OMB Number:	3235-0287
if no lon subject t Section Form 4 o Form 5 obligatio may con	obligations may continue. See InstructionSection 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940					Act of 1934, 1935 or Sectior	Expires: Estimated a burden hour response			
(Print or Type	Responses)									
1. Name and A Capponi Vi	Address of Reporting incent	S	ymbol	Name and			0	5. Relationship of Issuer	Reporting Pers	on(s) to
(Last)	(First) (N		Cytosorbents Corp [CTSO] (Chea				(Check	ck all applicable)		
C/O CYTO	SORBENTS ATION, 7 DEER P	() () ()		ay/Year)				Director X Officer (give below) Chief C		Owner r (specify er
	(Street)			ndment, Da hth/Day/Year	-			6. Individual or Joi Applicable Line) _X_ Form filed by O	ne Reporting Per	rson
MONMOU JUNCTION	TH N, NJ 08852							Form filed by M Person	ore than One Re	porting
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative S	Securi	ties Acqu	iired, Disposed of,	or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	4. Securiti n(A) or Dis (Instr. 3, 4	sposed	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
~				Code V	Amount	(D)	Price	(Instr. 3 and 4)		
Common Stock	06/14/2018			M <u>(1)</u>	11,367	А	\$ 3.75	319,350	D	
Common Stock	06/15/2018			M <u>(1)</u>	8,633	А	\$ 3.75	327,983	D	
Common Stock	06/15/2018			М	40,000	А	\$ 0.875	367,983	D	
Common Stock	06/14/2018			S <u>(1)</u>	11,367	D	\$ 12	356,616	D	
	06/15/2018			S (1)	8,633	D	\$12	347,983	D	

Edgar Filing:	Capponi	Vincent -	Form 4
---------------	---------	-----------	--------

			0 0 1	•					
Common Stock									
Common Stock	06/15/20	018	F	15,215	D \$ 12.35	332,768 <u>(2)</u>	D		
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.									
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisab Expiration Date (Month/Day/Year		7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amoun or Number of Share
Stock Option (right to buy)	\$ 3.45	06/14/2018		M (1)	11,367	05/05/2010 <u>(3)</u>	05/05/2020	Common Stock	11,36
Stock Option (Right to Buy)	\$ 3.45	06/15/2018		M <u>(1)</u>	8,633	05/05/2010 <u>(3)</u>	05/05/2020	Common Stock	8,633
Stock Option (Right to Buy)	\$ 0.875	06/15/2018		М	40,000	06/25/2011	06/25/2018	Common Stock	40,00

Reporting Owners

Reporting Owner Name / Address	Relationships					
F. S. S. S. S. S. S. S.	Director	10% Owner	Officer	Other		
Capponi Vincent C/O CYTOSORBENTS CORPORATION 7 DEER PARK DRIVE, SUITE K MONMOUTH JUNCTION, NJ 08852			Chief Operating Officer			

Signatures

/s/ Vincent Capponi

**Sign

06/18/2018

**Signature of	
Reporting Person	

Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance (1)with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) the following RSUs subject to vesting as to one-third of the

(2) award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting; (a) 11,980 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof, and (b) 25,334 RSUs granted on February 28, 2018 and unvested as of the date hereof and (iii) 88,454 shares of common stock owned by the reporting person.

These stock options vested at the discretion of the Company's Board of Directors based on satisfying certain criteria including a timely (3) completion of the sepsis trial, raising capital for the Company, and partnering and business development. The options did not vest on May 5, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.